Page 200 of 294: studies 1,991 to 2,000 of 2,936, newest first. Back to the psychedelic-assisted therapy overview
May 2, 2024 Hanna Brancaccio
Introduction: Substance use disorder (SUD) and alcohol use disorder (AUD) are major public health crises, affecting millions of Americans. Current treatment options include behavioral therapies and medications. In this review, we explored psilocybin’s efficacy in treating SUD and AUD. Methods: Key terms were used to search databases to identify articles that addressed psilocybin in the...
Social Work May 2, 2024 Claire Parker, Bethany Wood 2 citations
Abstract This article underscores the critical role of social workers in harnessing the potential therapeutic benefits of psilocybin for treating major depressive disorder (MDD) and substance use disorder (SUD). Contemporary treatments for MDD often have side effects, and the success rate for SUD treatments remains low. The pervasiveness of MDD, combined with the challenges in treating SUD,...
Nature Mental Health May 1, 2024 Joshua C. Black, Andrew A. Monte, Nabarun Dasgupta et al. 5 citations
The encouraging results of late-phase clinical trials investigating psychedelic-assisted psychotherapy suggests that US Food and Drug Administration approval and subsequent expansion of use is imminent in the USA. Without fit-for-purpose postmarket surveillance to proactively monitor utilization by patients and providers, there is a risk that the real-world benefits of psychedelic-assisted...
Journal of Neural Transmission May 1, 2024 Fahd François Hilal, Jérôme Jeanblanc, Chloé Deschamps et al. 8 citations
Alcohol use disorder (AUD) is a public health issue that affects millions of people worldwide leading to physical, mental and socio-economic consequences. While current treatments for AUD have provided relief to individuals, their effectiveness on the long term is often limited, leaving a number of affected individuals without sustainable solutions. In this review, we aim to explore two...
Der Nervenarzt May 1, 2024 Bernhard T Baune, Sarah E Fromme, Maximilian Kiebs et al. 1 citation
Treatment-resistant depression (TRD) is a complex disorder. Although no standardized definition has been established to date, there are promising and well-established treatment options for the condition. Looking at the current pharmacological and neuromodulatory strategies, there is an urgent need for fast-acting and well-tolerated treatment options. The search for new mechanisms of action goes...
Læknablaðið May 1, 2024 Helga Thorarinsdottir, Berglind Gudmundsdottir, Engilbert Sigurðsson 1 citation
MDMA is a potential novel treatment for post-traumatic stress disorder (PTSD). Our goal is to review current knowledge on MDMA and its use in MDMA-assisted psychotherapy for PTSD. Literature searches were done on PubMed, Web of Science and Google Scholar and references reviewed in identified articles. MDMA-assisted therapy for PTSD usually consists of a few preparatory sessions before two or...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging May 1, 2024 Balázs Szigeti, Boris D. Heifets 62 citations
Clinical trials of psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltrptamine (DMT) have forced a reconsideration of how nondrug factors, such as participant expectations, are measured and controlled in mental health research. As doses of these profoundly psychoactive substances increase, so does the difficulty in concealing the treatment condition in the...
Biological Psychiatry April 29, 2024 Joshua S. Siegel, Subha Subramanian, Nico U.f. Dosenbach et al. 14 citations
1 Summary The relationship between the acute effects of psychedelics and their persisting neurobiological and psychological effects is poorly understood. Here, we tracked brain changes with longitudinal precision functional mapping in healthy adults before, during, and for up to 3 weeks after oral psilocybin and methylphenidate (17 MRI visits per participant) and again 6+ months later....
EMBARK Psychedelic Therapy for Depression April 23, 2024 Bill Brennan, Alex Belser
AbstractChapter 3 describes proposed psychological mechanisms of change within the EMBARK psychedelic therapy model for the treatment of depression. Twelve mechanisms of therapeutic change are described across the six EMBARK clinical domains: Existential–Spiritual: (a) spiritual self-development, (b) mystical experiences; Mindfulness: (c) freedom from rumination, (d) a more flexible identity,...
EMBARK Psychedelic Therapy for Depression April 23, 2024 Bill Brennan, Alex Belser
AbstractChapter 4 provides a comprehensive guide to the considerations and treatment factors that should be attended to prior to initiating psychedelic-assisted therapy (PAT). It discusses the importance of therapists’ credentials, competencies, skills, personal growth, experiential training, personal psychedelic experiences, and personal commitment to receiving supervision, peer supervision,...